Hemorrhage profile associated with immune checkpoint inhibitors: a systematic review and a real-world study based on the FAERS database

References

• Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974–1982. doi: 10.1200/JCO.2014.59.4358
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD, et al. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168. doi: 10.1056/NEJMra1703481
   PubMed Web of Science ®Google Scholar
• Hassel JC, Heinzerling L, Aberle J, et al. Combined immune checkpoint blockade (anti-PD-1/anti CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev. 2017;57:36–49. doi: 10.1016/j.ctrv.2017.05.003
   PubMed Web of Science ®Google Scholar
• Pereira J, Phan T. Management of bleeding in patients with advanced cancer. Oncology. 2004;9(5):561–70. doi: 10.1634/theoncologist.9-5-561
   Google Scholar
• Dutcher JP. Hematologic abnormalities in patients with nonhematologic malignancies. Hematol Oncol Clin North Am. 1987;1(2):281–299. doi: 10.1016/S0889-8588(18)30676-2
   PubMedGoogle Scholar
• Jackson A, Skwarchuk MW, Zelefsky MJ, et al. Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys. 2021;49(3):685–698.
   Google Scholar
• McMahon BJ, Kwaan HC. Thrombotic and bleeding complications associated with chemotherapy. Semin Thromb Hemost. 2012;38(8):808–17. doi: 10.1055/s-0032-1328885
   PubMed Web of Science ®Google Scholar
• Zhu X, Tian X, Yu C, et al. Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: an updated meta-analysis of 12 randomized controlled trials. Medicine (Baltimore). 2016;95(34):e4232. doi: 10.1097/MD.0000000000004232
   PubMed Web of Science ®Google Scholar
• Hapani S, Sher A, Chu D, et al. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology. 2010;79(1–2):27–38. doi: 10.1159/000314980
   PubMed Web of Science ®Google Scholar
• Davis EJ, Salem JE, Young A, et al. Hematologic complications of immune checkpoint inhibitors. Oncol. 2019;24(5):584e8. doi: 10.1634/theoncologist.2018-0574
   Google Scholar
• Maio M, Scherpereel A, Calabrò L, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomized, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18(9):1261–1273.
   PubMed Web of Science ®Google Scholar
• Eng C, Kim TW, Bendell J, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomized, controlled trial. Lancet Oncol. 2019;20(6):849–861.
   PubMed Web of Science ®Google Scholar
• Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6(5):676–684.
   PubMed Web of Science ®Google Scholar
• Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51–65.
   PubMed Web of Science ®Google Scholar
• Zarzuela L, Loke YK, Ioannidis JP, et al. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. doi: 10.1136/bmj.i157
   PubMedGoogle Scholar
• Fairlie J-L, Ferrer P, Gouverneur A, et al. A new risk of bias checklist applicable to randomized trials, observational studies, and systematic reviews was developed and validated to be used for systematic reviews focusing on drug adverse events. J Clin Epidemiol. 2017;86:168–175. doi: 10.1016/j.jclinepi.2017.04.023
   PubMed Web of Science ®Google Scholar
• Higgins J, Thomas J Cochrane handbook for systematic reviews of interventions. Version 6.3 2022 [citedd 2022 May 14]. Available from: https://training.cochrane.org/handbook/current/chapter-10#section-10-10-2/
   Google Scholar
• Brinker A, Cheng C, Chan V. Association of Noninfectious Pneumonia With Ustekinumab Use. JAMA Dermatol. 2019;155(2):221–224. doi: 10.1001/jamadermatol.2018.4118
   PubMed Web of Science ®Google Scholar
• Ang PS, Chen Z, Chan CL, et al. Data mining spontaneous adverse drug event reports for safety signals in Singapore – a comparison of three different disproportionality measures. Expert Opin Drug Saf. 2016;15(5):583–590.
   PubMed Web of Science ®Google Scholar
• Hou YF, Ye XF, Wu GZ, et al. A comparison of disproportionality analysis methods in national adverse drug reaction databases of China. Expert Opin Drug Saf. 2014;13(7):853–857.
   PubMed Web of Science ®Google Scholar
• Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315–321.
   PubMed Web of Science ®Google Scholar
• Noren GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22(1):57–69. doi: 10.1177/0962280211403604
   PubMed Web of Science ®Google Scholar
• Kewan T, Covut F, Ahmed R, et al. Clinically significant bleeding with immune checkpoint inhibitors: a retrospective cohort study. Eur J Cancer. 2020;137:285–287. doi: 10.1016/j.ejca.2020.07.005
   PubMed Web of Science ®Google Scholar
• Grassadonia A, Sperduti I, Vici P, et al. Effect of gender on the outcome of patients receiving immune checkpoint inhibitors for advanced cancer: a systematic review and meta-analysis of phase III randomized clinical trials. J Clin Med. 2018;7(12):542.
   PubMed Web of Science ®Google Scholar
• Conforti F, Pala L, Bagnardi V, et al. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet Oncol. 2018;19:737–746. doi: 10.1016/S1470-2045(18)30261-4
   PubMed Web of Science ®Google Scholar
• O’Connor JM, Seidl-Rathkopf K, Torres AZ, et al. Disparities in the use of programmed death 1 immune checkpoint inhibitors. Oncology. 2018;23(11):1388–1390.
   Google Scholar
• Rastrelli M, Tropea S, Rossi CR, et al. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 2014;28(6):1005–1011.
   PubMed Web of Science ®Google Scholar
• Henley SJ, Richards TB, Underwood JM, et al. Lung cancer incidence trends among men and women — the United States, 2005–2009. MMWR Morb Mortal Wkly Rep. 2014;63:45. doi: 10.2307/24854841
   Web of Science ®Google Scholar
• Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38.
   PubMed Web of Science ®Google Scholar
• Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13(8):473–486.
   PubMed Web of Science ®Google Scholar
• El Osta B, Hu F, Sadek R, et al. Not all immune-checkpoint inhibitors are created equal: a meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol. 2017;119:1–12. doi: 10.1016/j.critrevonc.2017.09.002
   PubMed Web of Science ®Google Scholar
• Zhai Y, Ye X, Hu F, et al. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US food and drug administration adverse events reporting system. J Immunother Cancer. 2019;7(1):286.
   PubMed Web of Science ®Google Scholar
• Grimaldi AM, Marincola FM, Ascierto PA. Single versus combination immunotherapy drug treatment in melanoma. Expert Opin Biol Ther. 2016;16(4):433–441. doi: 10.1517/14712598.2016.1128891
   PubMed Web of Science ®Google Scholar
• Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28(10):2377–2385. doi: 10.1093/annonc/mdx286
   PubMed Web of Science ®Google Scholar
• Callahan MK, Yang A, Tandon S, et al. Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis. J Clin Oncol. 2011;29(15_suppl):319–321.
   Web of Science ®Google Scholar
• Tarhini AA, Zahoor, H., Lin, Y, et al. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015;3(1):39.
   PubMedGoogle Scholar
• Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev. 2014;13(6):668–677. doi: 10.1016/j.autrev.2013.12.004
   PubMed Web of Science ®Google Scholar
• Pico de Conan Y, Poschke l, Gentilcore G, et al. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their arginase1 production. Cancer Immunol Res. 2013;1(3):158–162. doi: 10.1158/2326-6066
   PubMed Web of Science ®Google Scholar
• Knochelmann HM, Dwyer, CJ., Bailey, SR, et al. When worlds collide: Th17 and Treg cells in cancer and autoimmunity. Cell Mol Immunol. 2018;15(5):458–469.
   PubMed Web of Science ®Google Scholar
• Kroll MH, Rojas-Hernandez C, Yee C. Hematologic complications of immune checkpoint inhibitors. Blood. 2022;139(25):3594–3604. doi: 10.1182/blood.2020009016
   PubMed Web of Science ®Google Scholar
• Nishino M, Gibbie-Hurder A, Hatabu H, et al. Incidence of programmed cell death 1 inhibitor–related pneumonitis in patients with advanced cancer. JAMA Oncol. 2016;2(12):1607–1616.
   PubMed Web of Science ®Google Scholar
• Chaudhary B, Elkord E. Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. Vaccines (Basel). 2016;4(3):28. doi: 10.3390/vaccines4030028
   PubMed Web of Science ®Google Scholar
• Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells. Immunol Cell Biol. 2018;96(1):21–33. doi: 10.1111/imcb.1003
   PubMed Web of Science ®Google Scholar
• Mayer K, Briese W, Blieninger J, et al. Development of skin rash predicts outcome of anti-PD-1- and anti-CTLA4-based immune checkpoint inhibitor therapy in non-small cell lung cancer or squamous cell carcinoma of the head and neck: a single-center analysis. Oncol Res Treat. 2021;44(10):538–546. doi: 10.1159/000518449
   PubMed Web of Science ®Google Scholar
• Russano M, Cortellini A, Giusti R, et al. Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. Cancer Immunol Immunother. 2022;71(4):865–874. doi: 10.1007/s00262-021-03045-9
   PubMed Web of Science ®Google Scholar
• Dong M, Yu T, Zhang Z, et al. Icis-related cardiotoxicity in different types of cancer. J Cardiovasc Dev Dis. 2022;9(7):203.
   PubMed Web of Science ®Google Scholar